Abstract: The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.

Abstract: Disclosed are an apparatus, a method, and a recording medium for controlling a portable communication terminal and a smart watch of the portable communication terminal, which control an operation of a display unit only when a user obtains information on a movement of the smart watch from a sensor installed in the smart watch and view the smart watch.

Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.

Abstract: A nanostructure is described. The nanostructure includes a nanoparticle, a shell encompassing the nanoparticle, and a gap having a width ranging from 1.0 nm to 6.0 nm and located between the nanoparticle and the shell to enable the nanostructure to generate a fluorescence.

Abstract: Provided is an electrolyte solution for a magnesium battery, containing a mesoionic compound represented by the following general formula (1): (in general formula (1), R1 and R2 are each independently a C1-7 hydrocarbyl group or oxygen-containing hydrocarbyl group and X is O or S).

Abstract: The invention is directed to polymers that self-crosslink at acidic pH or can be crosslinked by phenolic agents in brine. Such polymers have lower viscosity and can be pumped deep into reservoirs, where they will cross link in situ, thus increasing their viscosity and/or form a gel and blocking thief zones. Methods of making and using such polymers are also provided.

Abstract: The process disclosed herein produces macroscopic quantities of semiconducting arsenic sulfide nanofibers within one to three days. The process is biotically influenced by the bacteria Shewanella sp. Strain ANA-3. The fibers are semiconductors with bandgaps between 2.2 and 2.5 eV. Newly measured semiconducting and bandgap properties can lead to applications in the semiconductor, transistor, and solar energy fields. A faster and more robust biological component makes the overall process more commercially feasible than it would have been otherwise. The faster rate allows for larger yields of nanofibers in a predetermined period of time.

Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.

Abstract: An organic electrical device can include a first dielectric substrate including a PVDF-TrFe-CFE terpolymer, a first semiconductor region coupled to a first surface of the first dielectric substrate, and a first gate region coupled to a second surface of the first dielectric substrate, the second surface opposite the first surface and opposite the first semiconductor region. The organic electrical device can include an organic field-effect transistor (OFET), comprising the first gate region, the first dielectric substrate, a first source region, and a first drain region respectively electrically coupled to the first semiconductor region. An electrostrictive actuator or mechanical sensor can be co-integrated on the first dielectric substrate, the actuator or sensor including first and second conductive regions located on opposite surfaces of the first dielectric substrate. The actuator or sensor can be electrically coupled to the OFET, and controlled at least in part by the OFET.

Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.

Abstract: A photoplethysmograph device includes a light source for illuminating a target object. A modulator drives the light source such that the output intensity varies as a function of a modulation signal at a modulation frequency. A detector receives light from the target object and generates an electrical output as a function of the intensity of received light. A demodulator with a local oscillator receives the detector output and produces a demodulated output, insensitive to any phase difference between the modulation signal and the oscillator, indicative of blood volume as a function of time and/or blood composition. A number of demodulators may be provided to derive signals from multiple light sources of different wavelengths, or from an array of detectors. The plethysmograph may operate in a transmission mode or a reflectance mode. When in a reflectance mode, the device may use the green part of the optical spectrum and may use polarising filters.

Abstract: A method using optical coherence tomography to capture the microvascular network of the superficial layer of the finger skin for the purpose of fingerprint authentication and liveness detection. At the dermal papilla region, the vascular pattern follows the same pattern of the fingerprint and this vascular pattern forms a live vascular fingerprint. This live vascular fingerprint provides for ultrahigh security and a unique way for fingerprint-based personal verification. Because the system is based on blood flow, which only exists in a living person, the technique is robust against spoof attaching. After performing non-contact in-vivo imaging of a human fingertip, a three dimensional vasculature image is reconstructed from a plurality of vasculature tomography images and at least one vasculature fingerprint image which corresponds to the fingertip is extracted from the three dimensional vasculature image.

Abstract: The invention relates to methods of screening to find compounds that are cytotoxic to tumor cells and methods of treating tumor cells using these compounds. In particular, the invention relates to methods of screening for compounds that inhibit mammalian mitochondrial fatty acid synthase (mmFAS) and methods of treating tumor cells using mmFAS inhibitors. This invention also provides methods for inhibiting or preventing cancer cell survival by the administration of mitochondrial fatty acid synthase (FAS) inhibitors. Specifically, this invention describes a method for prohibiting or delaying the development of cancer, the growth of cancer or invasion of cancer from pre-malignant (noninvasive) lesions, or metastasis of cancer based upon the findings that this method compromises energy balance in cancer cells, in turn compromising their basic functions and causing their cell death.

Abstract: The present invention relates to compositions and methods for the prevention and treatment of atrial fibrillation. In particular, the present invention provides therapeutic agents for the treatment and prevention of persistent and permanent atrial fibrillation and prevention of progression of atrial fibrillation to permanent atrial fibrillation.

Abstract: Methods are provided for diagnosing pregnancy-associated disorders, determining allelic ratios, determining maternal or fetal contributions to circulating transcripts, and/or identifying maternal or fetal markers using a sample from a pregnant female subject. Also provided is use of a gene for diagnosing a pregnancy-associated disorder in a pregnant female subject.

Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Abstract: The present invention provides a method for diagnosing hypercoagulability associated with carbon monoxide exposure in a subject. The method comprises obtaining a plasma sample from the subject, dividing the sample into at least two portions, and determining the clot strength of the first portion. The method further comprises exposing the second portion to an organic reductant, determining the clot strength of the second portion after exposure to the organic reductant, and comparing the clot strength of the first portion with the clot strength of the second portion. A diagnosis of hypercogulability associated with carbon monoxide exposure is made when the clot strength of the second portion is decreased compared with the cloth strength of the first portion.

Abstract: A method, system or device for configuring an optical coupling device including obtaining characteristics of an optical signal and ambient conditions for storage in memory, utilizing a processor for identifying an optimum effective subwavelength area refractive index and a grating period for the input signal and ambient characteristics stored in memory, and utilizing the processor for identifying a preferred filling factor for a transverse polarization.

Abstract: The invention is directed to methods for generating pancreatic progenitor cells, insulin producing cells or endoderm cells using embryonic stem cells and induced pluripotent stem cells.

Abstract: A method of determining the susceptibility to ventricular arrhythmias in a subject, comprises the steps of: (a) collecting (e.g., by surface EKG or intracardiac EKG) at least one QT and DI interval data set from the subject during a stage of gradually increasing heart rate or a stage of gradually decreasing heart rate; (b) determining (e.g.